NCT03587662 2026-01-09
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT00068393 2023-07-07
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01164228 2023-06-15
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT00121251 2021-04-06
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01762150 2018-11-20
Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT00089102 2018-07-16
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT00496587 2017-07-19
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00401128 2017-04-20
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00004095 2017-04-18
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Northwestern University
Phase 1 Completed
NCT00630409 2017-03-10
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
University of Pittsburgh
Phase 2 Completed
NCT00042965 2016-07-14
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00556049 2016-04-21
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT00352859 2014-12-30
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
Bayer
Phase 4 Terminated
NCT00003664 2013-11-06
Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01834183 2013-06-19
Tivozanib + Gemcitabine in Metastatic RCC
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT00491075 2013-04-24
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00058318 2012-11-02
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00003928 2010-06-11
Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00323791 2009-12-11
Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00496301 2009-01-14
SOGUG-02-06
Spanish Oncology Genito-Urinary Group
Phase 2 Completed